:About the Medical Protection Bureau
The Medical Protection Bureau will become the most concerned government department of the pharmaceutical and medical equipment companies after the establishment of the Bureau. There are three reasons:
1. Market access
What is market access for the domestic pharmaceutical industry? We can narrowly understand: bidding, health insurance.
If the drugs cannot pass the bidding, they will lose the whole hospital market. In addition, if the drugs cannot enter the medical insurance catalog, even if they pass the bidding, it will have a great impact on their market.
Bidding and the health insurance catalog are both market access, and the importance of both rights is now in the hands of the Health Insurance Bureau.
2. Strict control of drug use
Medicare cost control clearly remains the key word for 2018. Under the big action of Medicare cost control, for pharmaceutical companies, entering the catalog is just a threshold, hospital access and Medicare payment standards are the top priority.
Medicare is empowered to control costs at the source and has direct control over previously high-dose drugs and ancillary medicines. In addition, under Medicare payment standards, hospitals will be prompted to treat patients with the least costly drugs based on rational drug use. In the future, the interests of all parties in the Medicare environment will be more obvious game.
3. Directly determine the price of drugs
Previously, drug prices were priced by the National Development and Reform Commission, the Ministry of Human Resources and Social Security was responsible for the health insurance catalog, and the Health and Family Planning Commission was responsible for bidding and purchasing, and ultimately paid for by health insurance. Those who spent the money couldn't talk about prices and standardized use, leading to increasing pressure on health insurance.
Today, the Bureau of Medical Insurance has taken over the bidding and purchasing of medicines, reflecting on the one hand the principle of "who pays, who makes the market". On the other hand, in the actual health insurance funds, the winning price of drugs will be closely linked to the health insurance payment standard, so as to maximize the interests of all parties.
In this case, hospitals or medical alliances can negotiate drug prices based on health insurance payment standards. They can even commission a third-party platform to negotiate drugs with local health insurance bureaus. There is only one ultimate goal. To reduce drug prices and maximize benefits based on health insurance payment standards.
It can be said that medical insurance will directly affect the fate of pharmaceutical companies and even businesses from a number of angles. By the Medical Security Bureau at the helm.